- Different rationale on whether you can log trade secret IP?
• Differences in industries?
• How companies operate that may provide different rationale
- What variables are available to track their trade secret?
- How their industries operate,
- Examine examples of cost/benefits of trade secret tracking
- How to effectively mark, catalogue trade secret – to avoid litigation
• What tools and controls are available.
• How many categories do you use?
- How do you define different sensitivity issue and audits.
Shane O`Neill
Shane O’Neill trained and qualified as a competition lawyer at Freshfields Bruckhaus Deringer where he advised clients in the aerospace and aviation sectors on merger control and antitrust regulatory matters. Since moving in-house he has advised on a broad range of matters including IT outsourcing, IP licensing, data protection, IPO, cybersecurity, commercial negotiations with aerospace OEMS, corporate transactions, and IP strategy.
Currently, he is Assistant General Counsel at Norsk Titanium, a global leader in metal 3D printing which supplies components to the aerospace, defence, and industrial sectors. He is responsible for a number of corporate areas including driving the company’s IP strategy, creation of IP awareness, trade secret protection, IP portfolio management, IP risk reduction, IP collaboration and cybersecurity.
Erica LoRe
Wil Rao
Laurence Shumway
Larry Shumway joined Flagship Pioneering in 2018 and serves as Vice President, Intellectual Property Counsel. He is responsible for developing, implementing, and managing IP and related legal strategies for Flagship’s enterprise companies, as well as setting institutional policies and designing educational courses.
He has more than 15 years of industry and law firm experience, specializing in biologics and biotechnology. As inhouse counsel at Takeda, GSK, and Novartis, he designed and managed complex IP portfolios around innovative large molecule platforms and assets in oncology, immunology, and vaccines, and led IP and legal functions on transactional and project teams. He began his legal career in the IP boutique firms of Hamilton, Brook, Smith and Reynolds, PC and Finnegan, LLP, focusing on evaluating and protecting complex biologics and inventions at the interface of biology with different technical fields.
Larry studied law at Boston College (J.D.) and earned his Ph.D. in biophysics from Harvard University on an NSF fellowship. He earned B.S. degrees in biochemistry and molecular biology and in mathematics and statistics from the University of Massachusetts, Amherst, on Goldwater, Beckman, and Pfizer scholarships.